ARVSMART.NSE News

Arvind SmartSpaces Limited has signed its largest residential project in Mumbai with a top-line potential of approximately Rs 2,400 crore, located in Goregaon West. The project offers around 0.67 million square feet of saleable area and will be developed in partnership with Sigma Oxford Realtors. Alongside this, the company executed strategic stake transactions to support the development.

Arvind SmartSpaces has entered Mumbai’s residential market with a ₹300 crore redevelopment project in Santacruz West. The project marks its first housing venture in MMR and highlights the company’s focus on redevelopment opportunities in high-demand urban micro-markets.

Arvind SmartSpaces will redevelop a housing society in Santacruz, Mumbai. The project is expected to generate Rs 300 crore in revenue. This development involves a total estimated carpet area of 42,000 square feet for sale. Arvind SmartSpaces has ongoing real estate projects in several major Indian cities.

Birla Estates and Arvind SmartSpaces are expanding into Mumbai's property market. They have launched new redevelopment projects in Khar West and Santacruz. These ventures tap into the city's demand for housing. These projects represent significant revenue potential for both companies.

Arvind SmartSpaces Limited, a prominent real estate developer under the Lalbhai group, has announced the acquisition of a new residential high-rise project in Whitefield, Bengaluru. The project, located in the…

… Enterprises, Lodha Developers, Aditya Birla Real Estate , and Arvind Smartspaces have significant … reporting healthy absorption. Aditya Birla Real Estate (ABREL), after a relatively quiet …

In this briefing: Understanding US Debt Dynamics - Dissecting the $38t Debt Aequitas: PhonePe Pre-IPO - The Negatives - Near Term Growth Might Be Capped Pharmaceuticals: IPM: steady 11% growth in Jan-26 Man Infraconstruction Ltd - Q3FY26: Slower Momentum; Recovery Awaited Arvind SmartSpaces Ltd - Q3FY26: Execution-Led Growth with Strengthening BD Momentum 1. Understanding US Debt Dynamics - Dissecting the $38t Debt Investors should not focus solely on the $38t in US public debt as it a headline figure over-reported and under- analysed Fears of using short-term debt as the main source of financing debt is misplaced. They are rolled over and do not 'add' to new debt unless deficits expand Teasury auction data does not show any signs of funding stress to date despite the widespread fears fanned by comments on Trump's fiscal policies 2. Aequitas: PhonePe Pre-IPO - The Negatives - Near Term Growth Might Be Capped Phonepe (PPL) is looking to raise up to US$1.35bn in its upcoming India IPO. PhonePe Ltd (PPL) is a fintech firm that builds digital platforms for payments services, digital distribution and financial services, offering consumer payments, merchant payments and lending and insurance distribution services.

In this briefing: Aequitas: PhonePe Pre-IPO - The Negatives - Near Term Growth Might Be Capped Pharmaceuticals: IPM: steady 11% growth in Jan-26 Man Infraconstruction Ltd - Q3FY26: Slower Momentum; Recovery Awaited Arvind SmartSpaces Ltd - Q3FY26: Execution-Led Growth with Strengthening BD Momentum Genus Power Infrastructures Ltd - Q3 Sees Seasonal Moderation; Tendering Progress Will Be the Key 1. Aequitas: PhonePe Pre-IPO - The Negatives - Near Term Growth Might Be Capped Phonepe (PPL) is looking to raise up to US$1.35bn in its upcoming India IPO. PhonePe Ltd (PPL) is a fintech firm that builds digital platforms for payments services, digital distribution and financial services, offering consumer payments, merchant payments and lending and insurance distribution services. In this note, we talk about the not-so-positive aspects of the deal. 2. Pharmaceuticals: IPM: steady 11% growth in Jan-26 As per IQVIA, IPM recorded strong growth for Jan-26 at 11% YoY (vs 15% in Dec-25), units grew by 1.1% YoY (4.4%% in Dec-25).

In this briefing: Pharmaceuticals: IPM: steady 11% growth in Jan-26 Man Infraconstruction Ltd - Q3FY26: Slower Momentum; Recovery Awaited Arvind SmartSpaces Ltd - Q3FY26: Execution-Led Growth with Strengthening BD Momentum Genus Power Infrastructures Ltd - Q3 Sees Seasonal Moderation; Tendering Progress Will Be the Key Britannia Industries Ltd. - Margin Stability Powering a Sharper Growth Revival; Maintain BUY 1. Pharmaceuticals: IPM: steady 11% growth in Jan-26 As per IQVIA, IPM recorded strong growth for Jan-26 at 11% YoY (vs 15% in Dec-25), units grew by 1.1% YoY (4.4%% in Dec-25). Growth was led by CVS, anti-diabetes, CNS, VMN, and oncology segments, while growth in anti-infective, gastro, respiratory, derma, and pain grew at par or marginal below compared to IPM growth. Our view: IPM growth was steady at 11% YoY in Jan-26, largely led by price growth and traction in chronic therapies. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.